• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的疗效和安全性：一项随机对照临床试验的荟萃分析。

Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials.

机构信息

Pathological teaching and research office, Gannan Health Vocational College, Ganzhou, Jiangxi, China.

Pathology department, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.

出版信息

Medicine (Baltimore). 2024 Jun 7;103(23):e38277. doi: 10.1097/MD.0000000000038277.

DOI:10.1097/MD.0000000000038277
PMID:38847673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11155537/
Abstract

BACKGROUND

We conducted this meta-analysis based on updated literature and research to compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as treatments for patients with non-small cell lung cancer (NSCLC).

METHODS

A literature search was conducted using PubMed, Embase, Medline and Web of Science databases to perform a systematic literature search based on random control trials. In these articles, EGFR-TKIs were compared with placebos, chemotherapy, or whole-brain irradiation as treatments for NSCLC. In this research, a meta-analysis of the literature was performed to produce a combined risk ratio (RR) with a 95% confidence interval (CI) for progression-free survival (PFS), overall survival (OS), and adverse events. The data were synthesized with Review Manager 5.3 software, which was used to manage the process.

RESULTS

There were 15 random control trials included in the study, involving 4249 patients in total. There was evidence that EGFR-TKIs can significantly prolong OS (RR: 0.87, 95% CI: 0.75-1) and PFS (RR: 0.75, 95% CI: 0.66-0.86) in NSCLC patients. There was an increase in the incidence of adverse events after treatment with EGFR-TKI, including diarrhea (RR: 0.18, 95% CI: 0.10-0.26), infection (RR: 0.09, 95% CI: 0.02-0.16), and rash (RR: 0.37, 95% CI: 0.22-0.51).

CONCLUSIONS

It has been shown that EGFR-TKIs prolong OS and PFS in patients with NSCLC. NSCLC patients may benefit from EGFR-TKIs as an important treatment option in order to prolong their survival.

摘要

背景

本研究基于最新文献和研究进行了荟萃分析，旨在比较表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）作为非小细胞肺癌（NSCLC）治疗方法的疗效和安全性。

方法

通过 PubMed、Embase、Medline 和 Web of Science 数据库进行文献检索，对随机对照试验进行系统文献检索。在这些文章中，将 EGFR-TKIs 与安慰剂、化疗或全脑放疗进行比较，作为 NSCLC 的治疗方法。本研究对文献进行荟萃分析，生成无进展生存期（PFS）、总生存期（OS）和不良事件的合并风险比（RR）及其 95%置信区间（CI）。使用 Review Manager 5.3 软件对数据进行综合处理。

结果

共有 15 项随机对照试验纳入研究，共纳入 4249 例患者。有证据表明，EGFR-TKIs 可显著延长 NSCLC 患者的 OS（RR：0.87，95%CI：0.75-1）和 PFS（RR：0.75，95%CI：0.66-0.86）。EGFR-TKI 治疗后不良反应发生率增加，包括腹泻（RR：0.18，95%CI：0.10-0.26）、感染（RR：0.09，95%CI：0.02-0.16）和皮疹（RR：0.37，95%CI：0.22-0.51）。

结论

EGFR-TKIs 可延长 NSCLC 患者的 OS 和 PFS。EGFR-TKIs 可作为 NSCLC 患者的重要治疗选择，以延长其生存期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/dc5032ece30e/medi-103-e38277-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/bc8b2020f1ea/medi-103-e38277-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/012b4d42fa76/medi-103-e38277-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/d65324c8eab9/medi-103-e38277-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/207435d66815/medi-103-e38277-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/2acc7f0095a2/medi-103-e38277-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/e8bdd07d238c/medi-103-e38277-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/5a2db430cf0b/medi-103-e38277-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/dc5032ece30e/medi-103-e38277-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/bc8b2020f1ea/medi-103-e38277-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/012b4d42fa76/medi-103-e38277-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/d65324c8eab9/medi-103-e38277-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/207435d66815/medi-103-e38277-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/2acc7f0095a2/medi-103-e38277-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/e8bdd07d238c/medi-103-e38277-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/5a2db430cf0b/medi-103-e38277-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6fe/11155537/dc5032ece30e/medi-103-e38277-g008.jpg

相似文献

1
Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的疗效和安全性：一项随机对照临床试验的荟萃分析。
Medicine (Baltimore). 2024 Jun 7;103(23):e38277. doi: 10.1097/MD.0000000000038277.
2
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.辅助 EGFR-TKIs 治疗可切除非小细胞肺癌的疗效和安全性：基于随机对照试验的系统评价和荟萃分析。
BMC Cancer. 2022 Mar 26;22(1):328. doi: 10.1186/s12885-022-09444-0.
3
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗。
Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3.
4
A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.第一代和新一代酪氨酸激酶抑制剂治疗非小细胞肺癌的比较的荟萃分析。
Math Biosci Eng. 2019 Jun 19;16(5):5687-5696. doi: 10.3934/mbe.2019283.
5
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
6
Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.贝伐珠单抗联合 EGFR-TKIs 治疗晚期非小细胞肺癌的疗效与安全性：Meta 分析。
Thorac Cancer. 2022 Jan;13(1):31-37. doi: 10.1111/1759-7714.14214. Epub 2021 Dec 3.
7
Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.下一代 EGFR-TKIs 在非小细胞肺癌患者中的疗效：一项随机对照试验的荟萃分析。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820940426. doi: 10.1177/1533033820940426.
8
[Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].化疗与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）联合与单纯化疗一线治疗晚期非小细胞肺癌的Meta分析
Zhongguo Fei Ai Za Zhi. 2016 Dec 20;19(12):837-846. doi: 10.3779/j.issn.1009-3419.2016.12.06.
9
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.表皮生长因子受体抑制剂作为表皮生长因子受体突变的可切除非小细胞肺癌的辅助治疗。
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
10
EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.表皮生长因子受体酪氨酸激酶抑制剂单药或联合化疗治疗表皮生长因子受体突变的非小细胞肺癌：一项随机对照试验的荟萃分析。
J Cancer Res Ther. 2021 Jul;17(3):664-670. doi: 10.4103/jcrt.JCRT_195_20.

引用本文的文献

1
Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis.ROS1酪氨酸激酶抑制剂在晚期非小细胞肺癌中的毒性特征：一项系统评价和比例Meta分析
Front Pharmacol. 2025 Aug 29;16:1644034. doi: 10.3389/fphar.2025.1644034. eCollection 2025.
2
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach.利用强化学习方法优化表皮生长因子受体突变的晚期非小细胞肺癌治疗决策
Cancers (Basel). 2025 Jan 13;17(2):233. doi: 10.3390/cancers17020233.

本文引用的文献

1
Treatment Strategies for Non-Small Cell Lung Cancer with Common Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data.常见突变非小细胞肺癌的治疗策略：表皮生长因子受体酪氨酸激酶抑制剂批准历程及新数据综述
Cancers (Basel). 2023 Jan 19;15(3):629. doi: 10.3390/cancers15030629.
2
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer.非小细胞肺癌中对表皮生长因子受体靶向治疗获得性耐药和耐受性的机制
Cancers (Basel). 2023 Jan 13;15(2):504. doi: 10.3390/cancers15020504.
3
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT).
吉非替尼对比顺铂联合长春瑞滨用于可切除的II-IIIA期非小细胞肺癌伴突变患者的随机III期研究（IMPACT）
J Clin Oncol. 2022 Jan 20;40(3):231-241. doi: 10.1200/JCO.21.01729. Epub 2021 Nov 2.
4
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.吉非替尼对比长春瑞滨联合顺铂用于 II-IIIA 期（N1-N2）表皮生长因子受体突变型非小细胞肺癌的辅助治疗：CTONG1104 期 III 临床试验最终总生存分析。
J Clin Oncol. 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. Epub 2020 Dec 17.
5
Update 2020: Management of Non-Small Cell Lung Cancer.更新于 2020 年：非小细胞肺癌的治疗。
Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.
6
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.奥希替尼对比铂类培美曲塞用于既往 EGFR 酪氨酸激酶抑制剂治疗进展的 EGFR T790M 阳性晚期 NSCLC 患者：AURA3 总生存分析。
Ann Oncol. 2020 Nov;31(11):1536-1544. doi: 10.1016/j.annonc.2020.08.2100. Epub 2020 Aug 27.
7
Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer.化疗仍然是治疗非小细胞肺癌的基石。
Curr Opin Oncol. 2020 Jan;32(1):63-67. doi: 10.1097/CCO.0000000000000592.
8
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.WJTOG3405 随机 III 期临床试验的最终总生存结果，比较吉非替尼与顺铂联合多西他赛作为 IIIB/IV 期或术后复发 EGFR 突变阳性非小细胞肺癌患者的一线治疗。
Ann Oncol. 2019 Dec 1;30(12):1978-1984. doi: 10.1093/annonc/mdz399.
9
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.非小细胞肺癌：流行病学、筛查、诊断和治疗。
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
10
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.安罗替尼治疗晚期非小细胞肺癌相关不良反应的管理：ALTER-0303 研究经验。
Thorac Cancer. 2019 Mar;10(3):551-556. doi: 10.1111/1759-7714.12977. Epub 2019 Jan 21.